Presentation is loading. Please wait.

Presentation is loading. Please wait.

Slide Source: Lipids Online www.lipidsonline.org Inflammation and CHD Inflammation and CHD Nathan Wong.

Published byEthan Lynch Modified over 8 years ago

Similar presentations

Presentation on theme: "Slide Source: Lipids Online www.lipidsonline.org Inflammation and CHD Inflammation and CHD Nathan Wong."— Presentation transcript:

1 Slide Source: Lipids Online www.lipidsonline.org Inflammation and CHD Inflammation and CHD Nathan Wong

2 Slide Source: Lipids Online www.lipidsonline.org Thrombosis, Inflammation, and Infection Many persons experiencing cardiovascular events often do not have well-recognized standard risk factors such as elevated cholesterol or hypertension. Thrombosis, local or systemic inflammation, and chronic infection may play important roles in the initiation and progression of CHD

3 Slide Source: Lipids Online www.lipidsonline.org Beyond Cholesterol: Predicting Cardiovascular Risk In the 21 st Century Cardiovascular Risk Lipids HTN Diabetes BehavioralBehavioral Hemostatic Thrombotic InflammatoryInflammatoryGeneticGenetic

4 Slide Source: Lipids Online www.lipidsonline.org Total Cholesterol Distribution: CHD vs Non-CHD Population 35% of CHD Occurs in People with TC<200 mg/dL 150 200 Total Cholesterol (mg/dL) 250 300 No CHD CHD Framingham Heart Study—26-Year Follow-up

5 Slide Source: Lipids Online www.lipidsonline.org Inflammation and Atherosclerosis Inflammation may determine plaque stability - Unstable plaques have increased leukocytic infiltrates - T cells, macrophages predominate rupture sites - Cytokines and metalloproteinases influence both stability and degradation of the fibrous cap Lipid lowering may reduce plaque inflammation - Decreased macrophage number - Decreased expression of collagenolytic enzymes (MMP-1) - Increased interstitial collagen - Decreased expression of E-selectin - Reduced calcium deposition

6 Slide Source: Lipids Online www.lipidsonline.org Is there clinical evidence that inflammatory markers predict future coronary events and provide additional predictive information beyond traditional risk factors?

7 Slide Source: Lipids Online www.lipidsonline.org Evaluating Novel Risk Factors for CAD Consistency of prospective data Strength of association Independence of association Improve predictive value Standardized measure Low variability High reproducibility Biologic plausibility Low cost Modifiable

8 Slide Source: Lipids Online www.lipidsonline.org Biomarkers for Venous and Arterial Thrombosis +++– hs-CRP / SAA / IL-6 / TNF +–Lp(a) ++–Platelet function ++–PAI-1: ag +++–tPA: ag ++–vWF: ag +–Factor VII +++–Fibrinogen ArterialVenousParameter

9 Slide Source: Lipids Online www.lipidsonline.org Biomarkers for Venous and Arterial Thrombosis (cont’d) ++ D-dimer ++ Homocysteine –+Protein S –+Protein C –++Anti-thrombin III –++Factor VIII –+Prothrombin –++Prothrombin mutation –+++Factor V Leiden ArterialVenousParameter

10 Slide Source: Lipids Online www.lipidsonline.org Thrombosis and Cardiovascular Risk Thrombus formation is a crucial factor in the precipitation of unstable angina or myocardial infarction, as well as occlusion during or following angioplasty. Often preceded by platelet aggregation and activation of the coagulation system. A thrombus may develop at sites of only mild to moderate coronary stenosis. The majority of coronary events occur where there is less than 70% stenosis. Occlusive coronary thrombosis plays a role in over 80% of myocardial infarctions and about 95% of sudden death victims.

11 Slide Source: Lipids Online www.lipidsonline.org Fibrinogen and Atherosclerosis Promotes atherosclerosis Essential component of platelet aggregation Relates to fibrin deposited and the size of the clot Increases plasma viscosity May also have a proinflammatory role Measurement of fibrinogen, incl. Test variability, remains difficult. No known therapies to selectively lower fibrinogen levels in order to test efficacy in CHD risk reduction via clinical trials.

12 Slide Source: Lipids Online www.lipidsonline.org Fibrinogen and CHD Risk: Epidemiologic Studies Recent meta-analysis of 18 studies involving 4018 CHD cases showed a relative risk of CHD of 1.8 (95% CI 1.6-2.0) comparing the highest vs lowest tertile of fibrinogen levels (mean.35 vs..25 g/dL) ARIC study in 14,477 adults aged 45-64 showed relative risks of 1.8 in men and 1.5 in women, attenuated to 1.5 and 1.2 after risk factor adjustment. Scottish Heart Health Study of 5095 men and 4860 women showed fibrinogen to be an independent risk factor for new events--RRs 2.2-3.4 for coronary death and all-cause mortality.

13 Slide Source: Lipids Online www.lipidsonline.org Fibrinogen and CHD Risk Factors Fibrinogen levels increase with age and body mass index, and higher cholesterol levels Smoking can reversibly elevated fibrinogen levels, and cessation of smoking can lower fibrinogen. Those who exercise, eat vegetarian diets, and consume alcohol have lower levels. Exercise may also lower fibrinogen and plasma viscosity. Studies also show statin-fibrate combinations (simvastatin-ciprofibrate) and estrogen therapy to lower fibrinogen.

14 Slide Source: Lipids Online www.lipidsonline.org Other Thrombotic Factors and CHD Mixed reports of coagulation factor VIIc in cardiovascular disease. PROCAM study showed no association with CHD events, CHS also showed no relation to subclinical CVD. Endogenous tissue-type plasminogen activator (tPA) shown in some studies to relate to increased cardiovascular risk--Physician’s Health Study showed RR for MI 2.8, stroke 3.5 in those in 5th vs. 1st quintile of tPA. Plasminogen activitor inhibitor type 1 (PAI-1) shown associated with increased cardiovascular risk, esp in diabetic patients.

15 Slide Source: Lipids Online www.lipidsonline.org Aspirin and Cardiovascular Risk: Clinical Trial Evidence for Primary Prevention US Physician’s Health Study- 22,071 male physicians - 44% reduction in MI risk, 13% nonsignificant increase in risk of stroke British Doctor’s Study of 5139 male physicians showed nonsignificant 3% reduction in MI risk,13% nonsignificant increase in stroke Hypertension Optimal Treatment (HOT) study among 18,790 pts w/htn showed 15% reduction in CVD events, 36% reduction in MI Ongoing Women’s Health Study (n=40,000)

16 Slide Source: Lipids Online www.lipidsonline.org Aspirin and Cardiovascular Risk: Clinical Trial Evidence for Secondary Prevention Antiplatelet Trialists Collaboration of 54,000 patients with cardiovascular disease (10 trials post-MI) showed 31% reduction in MI, 42% reduction in stroke, 13% reduction in total vascular mortality International Study of Infarct Survival of 17,187 pts w/evolving MI showed 49% reduction in reinfarction, 26% reduction in nonfatal stroke, and 23% reduction in total vascular mortality

17 Slide Source: Lipids Online www.lipidsonline.org Antiplatelet Therapy: AHA Recommendations Aspirin is clearly recommended in secondary prevention. Provides additional benefit in conjunction with thrombolytic therapy. Clopidogrel may be an option in aspirin-intolerant patients. Aspirin is not recommended for primary prevention in those free of CHD and younger than 50 years old. Aspirin may be considered in those over age 50 with additional risk factors, free of contraindications, and may benefit those with hypertension, diabetes, and cigarette smoking. American Diabetes Association recommends aspirin in diabetics with at least one other CHD risk factor.

18 Slide Source: Lipids Online www.lipidsonline.org Relative Risks of Future MI among Apparently Healthy Middle-Aged Men: Physician’s Health Study Relative Risk for Future MI 0 1.02.04.06.0 Lipoprotein(a) Homocysteine Fibrinogen tPA Antigen hs-CRP hs-CRP + TC/HDL-C Total Cholesterol TC:HDL-C

19 Slide Source: Lipids Online www.lipidsonline.org Risk Factors for Future Cardiovascular Events: WHS Relative Risk of Future Cardiovascular Events 0 Lipoprotein(a) Homocysteine IL-6 TC LDL-C sICAM-1 SAA Apo B TC:HDL-C hs-CRP hs-CRP + TC:HDL-C 1.02.04.06.0

20 Slide Source: Lipids Online www.lipidsonline.org CRP vs hs-CRP CRP is an acute-phase protein produced by the liver in response to cytokine production (IL-6, IL-1, tumor necrosis factor) during tissue injury, inflammation, or infection. Standard CRP Standard CRP tests determine levels which are increased up to 1,000-fold in response to infection or tissue destruction, but cannot adequately assess the normal range High-sensitivity CRP High-sensitivity CRP (hs-CRP) assays (i.e. Dade Behring) detect levels of CRP within the normal range, levels proven to predict future cardiovascular events.

21 Slide Source: Lipids Online www.lipidsonline.org Potential Mechanisms Linking CRP to Atherothrombosis Confounding by cigarette consumption Innocent bystander - Acute phase response Cytokine surrogate - IL-6, TNF-, IL-1 Direct effects of CRP - Innate immunity - Complement activation - CAM induction Prior infection - Chlamydia, H pylori, CMV Marker for subclinical atherosclerosis - EBCT / IMT / ABI Marker for insulin resistance/ obesity Marker for endothelial dysfunction Marker for dysmetabolic syndrome Marker for plaque vulnerability

22 Slide Source: Lipids Online www.lipidsonline.org hs-CRP and Risk of Future MI in Apparently Healthy Men 1 <0.055 Relative Risk of MI P = 0.03 Quartile of hs-CRP (range, mg/dL) 2 0.056–0.114 3 0.115–0.210 4 >0.211 P < 0.001 P Trend <0.001

23 Slide Source: Lipids Online www.lipidsonline.org hs-CRP and Risk of Future Stroke in Apparently Healthy Men 1 <0.055 Relative Risk of Ischemic Stroke Quartile of hs-CRP (range, mg/dL) 2 0.056–0.114 3 0.115–0.210 4 >0.211 P =0.02 P Trend <0.03

24 Slide Source: Lipids Online www.lipidsonline.org hs-CRP and Risk of Developing PVD in Apparently Healthy Men None hs-CRP (mg/dL) Intermittent Claudication Peripheral Artery Surgery

25 Slide Source: Lipids Online www.lipidsonline.org hs-CRP and Risk of Future Cardiovascular Events in Apparently Healthy Women 1 <0.15 Relative Risk Quartile of hs-CRP (range, mg/dL) 2 0.15–0.37 3 0.37–0.73 4 >0.73 P Trend <0.002 Any Event MI or Stroke

26 Slide Source: Lipids Online www.lipidsonline.org hs-CRP and Risk of Future Cardiovascular Events in Apparently Healthy Women: Low-Risk Subgroups 1 <0.15 Relative Risk Quartile of hs-CRP (range, mg/dL) 2 0.15–0.37 3 0.37–0.73 4 >0.73 No hypertension No hyperlipidemia No current smoking No diabetes No family history

27 Slide Source: Lipids Online www.lipidsonline.org hs-CRP and Coronary Heart Disease in Initially Healthy Men: MONICA–Augsburg Cohort 1 <0.6 Rate Ratio (Age Adjusted) Quartile of CRP (mg/dL) 2 0.6–1.1 3 1.1–2.2 4 2.2–4.5 5 >4.5

28 Slide Source: Lipids Online www.lipidsonline.org hs-CRP as a Risk Factor for Future CVD 1.02.03.04.05.06.0 Relative Risk (upper vs lower quartile) CHD Death MI Stroke CHD PVD CVD CHD 0 MRFIT ( Kuller 1996) PHS (Ridker 1997) CHS/RHPP (Tracy 1997) PHS (Ridker 1998) WHS (Ridker 1998, 2000) MONICA (Koenig 1999) Helsinki (Roivainen 2000) Caerphilly (Mendall 2000) Britain (Danesh 2000)

29 Slide Source: Lipids Online www.lipidsonline.org hs-CRP Adds to the Predictive Value of Total Cholesterol in Determining Risk of First MI Adjusted Relative Risk CRP >75 th percentile TC >75 th percentile –+–+ –+–+ P = 0.02 P = 0.001 P = 0.002

30 Slide Source: Lipids Online www.lipidsonline.org hs-CRP Adds to Predictive Value of TC:HDL Ratio in Determining Risk of First MI Total Cholesterol:HDL Ratio hs-CRP

31 Slide Source: Lipids Online www.lipidsonline.org Quartile of TC: HDL-C Quartile of hs-CRP 4 3 2 1 1 2 3 4 98765432109876543210 hs-CRP, Lipids, and Risk of Future Coronary Events: Women's Health Study (WHS)

32 Slide Source: Lipids Online www.lipidsonline.org Relative Risks for First MI for Baseline sICAM-1 >260 ng/dL Years of Study Follow-up 0–1 32103210 1–22–44–8 Relative Risk

33 Slide Source: Lipids Online www.lipidsonline.org Predictivity of Interleukin-6 on CV Risk in Women 4321043210 High Medium Low High Medium Low Interleukin-6 Total cholesterol

Download ppt "Slide Source: Lipids Online www.lipidsonline.org Inflammation and CHD Inflammation and CHD Nathan Wong."

Similar presentations

Emerging Cardiac Risk Factors Jon W. Wahrenberger, MD FACC DHMC Cardiology Update Symposium 2003 December 1, 2003.

Emerging Cardiac Risk Factors Jon W. Wahrenberger, MD FACC DHMC Cardiology Update Symposium 2003 December 1, 2003.
© Copyright 2009 by the American Association for Clinical Chemistry LOX Index, a Novel Predictive Biochemical Marker for Coronary Heart Disease and Stroke.

© Copyright 2009 by the American Association for Clinical Chemistry LOX Index, a Novel Predictive Biochemical Marker for Coronary Heart Disease and Stroke.
New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.

New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.
Presenter Disclosure Information Paul M Ridker, MD, FACC Dr Ridker is listed as a co-inventor on patents held by the Brigham and Women’s Hospital that.

Presenter Disclosure Information Paul M Ridker, MD, FACC Dr Ridker is listed as a co-inventor on patents held by the Brigham and Women’s Hospital that.
Inflammation, Thrombosis, Infection, and CARDIOVASCULAR DISEASE Nathan D Wong, PhD, FACC Professor and Director Heart Disease Prevention Program University.

Inflammation, Thrombosis, Infection, and CARDIOVASCULAR DISEASE Nathan D Wong, PhD, FACC Professor and Director Heart Disease Prevention Program University.
Slide Source LipidsOnline www.lipidsonline.org CO O C CH 3 COOCH CH 3 Cl CH 3 OC COOC 2 H 5 CH 3 Cl CH 3 OCH 2 CH 3 COOH CH 3 C Fenofibrate Clofibrate.

Slide Source LipidsOnline CO O C CH 3 COOCH CH 3 Cl CH 3 OC COOC 2 H 5 CH 3 Cl CH 3 OCH 2 CH 3 COOH CH 3 C Fenofibrate Clofibrate.
Slide Source: Lipids Online Slide Library www.lipidsonline.org Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:1349-57.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels Results of AFCAPS/TexCAPS John R. Downs, Michael.

Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels Results of AFCAPS/TexCAPS John R. Downs, Michael.
Cholesterol quintile (mg/dL)

Cholesterol quintile (mg/dL)
Childe Hassam: “The South Ledges” Early 20 th Century American Impressionist: Note: light And color! (Very European…)

Childe Hassam: “The South Ledges” Early 20 th Century American Impressionist: Note: light And color! (Very European…)
Chapter 4 Cardiovascular disease

Chapter 4 Cardiovascular disease
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?

Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Lesson 1 What is Coronary Artery Disease? Coronary Artery Disease also known as Coronary Heart Disease.

Lesson 1 What is Coronary Artery Disease? Coronary Artery Disease also known as Coronary Heart Disease.
C-REACTIVE PROTEIN, FIBRINOGEN, AND CARDIOVASCULAR DISEASE PREDICTION By Patrick Whitledge PA-S2 South University Physician Assistant Program.

C-REACTIVE PROTEIN, FIBRINOGEN, AND CARDIOVASCULAR DISEASE PREDICTION By Patrick Whitledge PA-S2 South University Physician Assistant Program.
Risk factors of Heart disease Dr. Mahmoudian.. Risk factors for coronary artery atherosclerosis Hyperlipidemia and dyslipidemia Hypertension Cigarette.

Risk factors of Heart disease Dr. Mahmoudian.. Risk factors for coronary artery atherosclerosis Hyperlipidemia and dyslipidemia Hypertension Cigarette.
Slide Source: Lipids Online www.lipidsonline.org Plasma Concentration of TNF- and Risk of Recurrent Coronary Events 2.5 2.0 1.5 1.0 0–2.47 (1 st –50 th.

Slide Source: Lipids Online Plasma Concentration of TNF- and Risk of Recurrent Coronary Events –2.47 (1 st –50 th.
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.

Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.

{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
MI: Risk Factors and Primary Prevention. Risk Factors Factors that appear to increase the general population’s chances of experiencing a health problem.

MI: Risk Factors and Primary Prevention. Risk Factors Factors that appear to increase the general population’s chances of experiencing a health problem.

Similar presentations

Ads by Google